JP2021504420A5 - - Google Patents

Download PDF

Info

Publication number
JP2021504420A5
JP2021504420A5 JP2020529534A JP2020529534A JP2021504420A5 JP 2021504420 A5 JP2021504420 A5 JP 2021504420A5 JP 2020529534 A JP2020529534 A JP 2020529534A JP 2020529534 A JP2020529534 A JP 2020529534A JP 2021504420 A5 JP2021504420 A5 JP 2021504420A5
Authority
JP
Japan
Prior art keywords
synthetic composition
hmo
human
gastrointestinal
human milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/059501 external-priority patent/WO2019106620A1/en
Publication of JP2021504420A publication Critical patent/JP2021504420A/ja
Publication of JP2021504420A5 publication Critical patent/JP2021504420A5/ja
Pending legal-status Critical Current

Links

JP2020529534A 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 Pending JP2021504420A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (2)

Publication Number Publication Date
JP2021504420A JP2021504420A (ja) 2021-02-15
JP2021504420A5 true JP2021504420A5 (https=) 2022-01-06

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529534A Pending JP2021504420A (ja) 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物

Country Status (7)

Country Link
US (1) US20200323921A1 (https=)
EP (1) EP3716983A4 (https=)
JP (1) JP2021504420A (https=)
KR (1) KR102741265B1 (https=)
CN (1) CN111683665A (https=)
BR (1) BR112020010843A2 (https=)
WO (1) WO2019106620A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
CN113194960A (zh) 2018-12-19 2021-07-30 格礼卡姆股份公司 用于治疗使用低fodmap饮食的人的组合物和方法
EP3897663A4 (en) * 2018-12-21 2022-09-07 Glycom A/S COMPOSITION AND METHOD FOR PROMOTING HEALING OF THE INTESTINAL BARRIER
KR20220017988A (ko) * 2019-06-05 2022-02-14 글리콤 에이/에스 비-셀리악 밀 및/또는 글루텐 민감성을 앓고 있는 환자에서 증상 치료에 사용하기 위한 모유 올리고사카라이드
JP2022548785A (ja) * 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
CA3178744C (en) 2020-05-13 2023-11-14 Ardythe L. Morrow Fucosylated oligosaccharides for prevention of coronavirus infection
WO2021231750A1 (en) * 2020-05-13 2021-11-18 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
EP4188391A1 (en) * 2020-07-31 2023-06-07 Abbott Laboratories Method of preventing, reducing or delaying fatty liver disease
CN116490079A (zh) * 2020-12-04 2023-07-25 雀巢产品有限公司 用于在个体中使用以支持夜间睡眠持续时间的包含人乳低聚糖的组合物
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
ES2651067T3 (es) * 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
EP2944690B1 (en) * 2010-10-11 2017-12-20 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
PT2672844E (pt) * 2011-02-10 2015-02-04 Nestec Sa Modulação do crescimento de bifidobactérias utilizando uma combinação de oligossacáridos identificados no leite humano
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
HK1199607A1 (en) * 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
WO2013161820A1 (ja) * 2012-04-23 2013-10-31 国立大学法人京都大学 ビフィズス菌の増殖促進用組成物
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
US20160120915A1 (en) * 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
PL3209673T5 (pl) * 2014-10-24 2023-10-23 Glycom A/S Mieszaniny hmo
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10881674B2 (en) * 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
CN107404925A (zh) * 2015-03-05 2017-11-28 雀巢产品技术援助有限公司 用于预防或治疗婴儿或幼儿胃肠感染/炎症的组合物
ES2886951T3 (es) * 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
CN108367031A (zh) * 2015-10-05 2018-08-03 瑞士达沃斯高山气候和医学研究院 嗜黏蛋白阿克曼氏菌用于治疗炎症病况的用途
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
RU2744199C2 (ru) * 2016-01-26 2021-03-03 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигосахариды грудного молока, применяемая для младенцев или детей младшего возраста в целях профилактики или лечения аллергических реакций
WO2018157900A1 (en) * 2017-03-01 2018-09-07 Glycom A/S Synthetic composition for microbiota modulation
EP3634429A4 (en) * 2017-05-09 2020-11-04 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception

Similar Documents

Publication Publication Date Title
JP2021504420A5 (https=)
Yan et al. Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters
Weber et al. Dietary fiber mixture in pediatric patients with controlled chronic constipation
JP2017533915A5 (https=)
JP2014528474A5 (https=)
JP2021504421A5 (https=)
CN105106245A (zh) Akkermansia muciniphila BAA-835菌株的应用
US20240299292A1 (en) Stable semi-solid chewable gel compositions and methods of making and using thereof
JP2020178685A (ja) 腸管障害の予防、治療又は抑制用組成物
CN104107188A (zh) 苹果多糖调节肠道菌群失调及润肠通便的用途及其制备方法
Serra et al. Prebiotic intake in older adults: effects on brain function and behavior
Fernandez-Martinez et al. A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters
CN110448569B (zh) 一种具有止泻功效的组合物及其制备方法和其应用
Mehjabin et al. Role of inulin in the management of metabolic disorders
US8840938B2 (en) Bioavailability enhancing composition
CN108653298A (zh) 单糖组合物、药物制剂及其应用
WO2023284778A1 (zh) 一种益生元组合物及其应用
CN107921058B (zh) 菊糖对鼻窦炎的预防作用
CN105451749B (zh) 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用
CN109999044B (zh) 一种含有醉茄素a的组合物及其应用
JP6940265B2 (ja) 止瀉剤組成物
EP3097921A1 (en) Composition comprising active ingredients of vegetable origin
JP2009263384A (ja) Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬
Hoffman Centrality of the GI Tract to Overall Health and Functional Medicine Strategies for GERD, IBS, and IBD
Rajalakshmi et al. Cancer Risk in Alterations of Prebiotics